Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17986813 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL18669621 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1948729 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL29984534 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL15116885 | 0.89 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL30591306 | 0.89 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL18094053 | 0.89 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL18611180 | 0.89 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL30505549 | 0.88 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL25286674 | 0.88 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380347-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-12-01 | — | — | US | disclosed |
| WO-2021212039-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380347-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | HSD17B10 1711/4885SMN1; SMN2 4032/4885NR1H2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.